DURAGESIC-25
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURAGESIC-25 is a transdermal extended-release film formulation of fentanyl, a potent opioid analgesic. The 25 mcg/hour patch delivers continuous pain relief through the skin over 72 hours. It is indicated for chronic pain management in opioid-tolerant patients.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling smaller, defensive brand teams focused on retention and generics management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DURAGESIC-25 offers limited growth trajectory but provides deep expertise in mature portfolio management, generic competition strategy, and opioid market dynamics. Roles focus on defensive positioning, payer negotiations, and retention of remaining market share rather than expansion.
Brand ManagerField Sales Representative
Worked on DURAGESIC-25 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.